查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1830999

单核细胞活化测试市场

Monocyte Activation Tests Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

2024 年单核细胞活化测试市值为 8,957 万美元，预计到 2031 年将达到 2.8448 亿美元，2025 年至 2031 年的复合年增长率预计为 17.5%。

分析师的观点

单核细胞活化检测市场分析突显了关键驱动因素，例如患者日益增长的安全担忧，以及製药、生物技术和医疗器材等行业对更安全的热原检测方法的需求日益增长。此外，单核细胞活化检测方法相关技术的进步预计将在整个预测期内推动市场成长。

依来源划分，单核细胞活化测试市场分为PMBC和细胞株两类。 PMBC细分市场在2022年占据了较大的市场份额，预计在预测期内将保持这一趋势。就产品而言，市场分为MAT试剂盒和试剂，其中MAT试剂盒细分市场在2022年也占据了较大的份额，预计这一趋势将持续下去。相反，预计试剂细分市场在预测期内将经历更高的复合年增长率。市场已按应用进一步细分为药物开发、疫苗开发、医疗器材和其他（例如研究）领域。药物开发细分市场在2022年占据了最大的份额，预计在2022年至2030年期间将保持这一趋势。

单核细胞活化试验 (MAT) 可识别由于内毒素和非内毒素热原共同作用而导致的细胞激素释放增强。 MAT 是一种体外检测方法，旨在评估肠外给药、生物製剂和医疗器材中所有类型热原的含量。在过去五年中，先前依赖兔热原试验进行释放检测的疫苗已率先采用单核细胞活化试验 (MAT)。与 MAT 不同，细菌内毒素检测通常不适用于本身俱有热原性或含有疫苗中常见添加剂（例如氢氧化铝）的产品，因为这些添加剂会干扰检测。 MAT 在疫苗检测中的应用范例包括脑膜炎奈瑟菌疫苗、高免血清、脑膜炎双球菌疫苗、黄热病疫苗、宋内志贺氏菌疫苗、狂犬病疫苗、B型肝炎疫苗和蜱传脑炎病毒疫苗。

战略洞察

市场洞察

医疗器材产业需求不断成长

单核细胞活化试验 (MAT) 是一种基于人类细胞的检测方法，用于检测和量化细菌、真菌和病毒等热原。 MAT 采用 ELISA 检测来测量处理后的血球释放的细胞激素。儘管 MAT 广泛可用，但在评估医疗器材的生物相容性时，它们很少用作基于动物的热原试验的替代品。 2018 年 9 月，美国国家毒理学计划替代毒理学方法评估跨部门中心 (NICEATM) 和 PETA 国际科学联盟有限公司 (PISC) 在美国国立卫生研究院举办了一场研讨会，讨论在医疗器材测试中实施 MAT 的必要步骤。据 DXC Technology Company 旗下公司 Luxoft 称，医疗器材透过预测演算法和患者资料分析实现准确的诊断、有效的治疗和个人化护理，从而促进医疗保健的数位转型。个人化医疗、植入式设备、智慧医疗设备和非侵入性手术领域的创新正在改变医疗保健格局，提供更优质的照护、更佳的患者预后并降低成本。医疗器材产业的成长反过来又推动了单核细胞活化检测方法的扩展，预计在预测期内这一趋势将持续下去。

市场机会单核细胞活化测试方法的技术进步

单核细胞活化试验方法最初是作为动物试验的替代方案引入，旨在提供在人体体外环境中进行热原检测的机会。单核细胞活化试验 (MAT) 于 2010 年在国际验证出版物发布后被纳入欧洲药典 (EP)。市场参与者不断创新和改进 MAT 检测方法和试剂，显着提高了重现性、灵敏度和特异性，使其成为可靠且更安全的热原检测选择。 MAT 检测方法用于鑑定肠外产品（包括药品和医疗器材）中的内毒素和非内毒素热原。通常，MAT 可作为传统动物试验的体外替代方案，符合监管指南的要求。兔热原检测和鲎试剂 (LAL) 检测是热原检测的常用方法，但这两种方法都涉及动物实验，且有一定的限制。兔热原检测缺乏稳定性，因为动物反应可能与人类反应不同。此外，LAL 检测仅检测内毒素，会忽略样本中可能存在的非内毒素热原，从而带来安全风险。为了解决这些局限性，单核细胞活化试验 (MAT) 于 2010 年被纳入《欧洲药典》，作为替代兔热原检测法（欧洲药典第 2.6.30 章）的药典方法，并被纳入 FDA 行业指南。市场参与者不断创新和开发 MAT 检测方法和试剂，从而提高了重现性、灵敏度和特异性，使其成为一种可靠且更安全的热原检测方法。

报告细分和范围基于来源的洞察

依来源划分，单核细胞活化测试市场分为週边血单核细胞（PMBC）和细胞株两类。 PMBC 细分市场在 2022 年占据了较大的市场份额，预计在预测期内将保持这一趋势，并预计 2022 年至 2030 年的复合年增长率更高。目前，全球有两种商业化的单核细胞活化测试细胞来源：Mono-Mac-6 (MM6)细胞株和周边血单核细胞 (PBMC)。 MM6细胞株来自单一急性单核细胞白血病患者的血液，这可能导致单核细胞无法像健康人一样持续表达检测致热原污染物和触发细胞因子释放所必需的 TLR。因此，使用此细胞来源的 MAT 结果的可重复性较低。欧洲药典 (2.6.30) 也规定，基于 MM6 的 MAT 试剂盒检测非内毒素致热原的能力「有限」。相较之下，基于PBMC的MAT试剂盒采用来自已筛选健康捐赠者的混合血的PBMC，从而能够更准确地模拟与加标产品样本孵育时的人类单核细胞活化。因此，基于此细胞来源的MAT试剂盒始终表现出可重复的结果。欧洲药典(2.6.30)认可此细胞来源能够高效检测内毒素和非内毒素热原。

目前，市场上还有另外三家基于PBMC的商业化单核细胞活化检测供应商，其检测极限 (LoD) 分别为0.125 EU/ml、0.02 EU/ml和0.016 EU/ml。 CTL-MAT检测的LoD为0.004 EU/ml，处于市场领先水平，是全球灵敏度最高的单核细胞活化检测之一。

基于产品的洞察就产品而言，单核细胞活化测试市场分为 MAT 试剂盒和试剂。 MAT 试剂盒细分市场在 2022 年占据了较大的市场份额，预计在预测期内将延续这一趋势；而试剂细分市场预计在预测期内将经历更高的复合年增长率。

基于应用的洞察按应用，单核细胞活化测试市场分为药物开发、疫苗开发、医疗器材和其他（如研究）。药物开发领域在 2022 年占据了最大份额，预计从 2022 年到 2030 年将保持这一趋势。根据美国国家医学图书馆的数据，药品是一类新兴的有机化合物，可显着改善患者的生活品质。製药业参与品牌药和仿製药的生产、开发和行销。 2014 年全球医药收入首次超过 1 兆美元。自 2017 年以来，医药市场一直以每年 5.8% 的速度成长，2017 年全球医药市场收入达到 11,430 亿美元，2021 年达到 14,620 亿美元。单核细胞活化测试（MAT）旨在评估肠外药物、生物製剂和医疗器材的所有类别的热原。肠外给药的药品必须不含致热原（引起发烧）污染，因为这些物质可能在患者的先天免疫系统中引发危及生命的全身反应。确保生物製品在给予患者前不含污染性的致热原物质至关重要。最初，兔热原试验 (RPT) 和细菌内毒素试验 (BET)/鲎试剂 (LAL) 被用作离体实验。

然而，严格的动物试验方法法规迫使市场参与者开发替代方法，以最大限度地减少动物使用。鑑于RPT和BET的局限性，以及复杂产品产量的不断增加，欧洲药典引入了MAT活化测试方法，该方法模拟人体免疫反应，并结合了RPT（评估革兰氏阴性内毒素以外的致热原性）和体外方法的优势。与RPT不同，MAT可以作为完全定量的测试，无需使用动物，这使得它更适用于固有致热原疫苗，并且由于其利用的是人体细胞，因此具有生理相关性。 MAT检测方法可以检测血液衍生产品、细胞衍生产品、生物製剂和疫苗。 MAT检测方法还可以评估各种药品和医疗器械，包括无法进行体内测试的产品（例如，含有透明质酸的产品）。这些因素促进了近年来单核细胞活化测试市场的整体成长，预计在预测期内将继续保持这一趋势。

单核细胞活化测试市场报告范围区域分析

从区域来看，单核细胞活化测试市场细分为北美、欧洲、亚太地区、南美和中美以及中东和非洲。北美在2022年占据最大市场份额，预计在预测期内将保持这一趋势，其次是欧洲。美国药典 (USP) 和加拿大政府等机构对单核细胞活化测试的监管实践进一步刺激了该地区单核细胞活化测试市场的整体成长。此外，对病患安全和医疗效果改善的日益关注也促进了北美市场的成长。

单核细胞活化测试市场的领先公司包括德国达姆施塔特默克公司和/或其附属公司、Charles River Laboratories International, Inc.、赛默飞世尔科技、Sanquin 和龙沙集团。

2023年10月，龙沙推出了两款新的快速单核细胞活化检测 (MAT) 系统：PyroCell MAT 快速系统和 PyroCell MAT 人类血清 (HS) 快速系统，旨在简化和加速兔无热原检测。这些系统将取代龙沙传统的 MAT 系统试剂盒产品。新推出的产品采用了全新的 PeliKine 人类 IL-6 快速 ELISA 试剂盒，可减少手动操作时间，并将结果获取时间从两天缩短至两小时。新的检测方法为製药和生物技术製造商提供了更方便的 MAT 检测选项，用于产品安全测试，同时有助于减少对动物测试的依赖。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：单核球活化测试市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：单核球活化测试市场-关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：单核球活化测试市场-全球市场分析

  • 单核细胞活化测试 - 全球市场概览
  • 单核细胞活化测试－全球市场及2030年预测

第 7 章：单核细胞活化测试市场 - 收入分析 - 按来源，2020-2030 年

  • 概述
  • 前胸腔外科委员会
  • 细胞株

第 8 章：单核球活化测试市场 - 收入分析 - 按产品，2020-2030 年

  • 概述
  • MAT 套件
  • 试剂

第 9 章：单核细胞活化测试市场 - 收入分析 - 按应用，2020-2030 年

  • 概述
  • 药物开发
  • 疫苗研发
  • 医疗器材
  • 其他（研究等）

第 10 章：单核细胞活化测试市场 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：新冠疫情前后的影响

第 12 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 13 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 14 章：单核细胞活化测试市场 - 主要公司简介

  • Merck KGaA, Darmstadt,Germany and/or its Affiliates
  • Charles River Laboratories International, Inc.
  • Thermo Fisher Scientific
  • Sanquin
  • Lonza Group
  • MAT Biotech
  • Cellmade Laboratories
  • Labor LS SE & Co. KG
  • BD Biosciences
  • Beckman Coulter

第 15 章：附录

简介目录
Product Code: TIPRE00004912

The monocyte activation tests market was valued at US$ 89.57 million in 2024 and is projected to reach US$ 284.48 million by 2031, with an estimated CAGR of 17.5% from 2025 to 2031.

Analyst's Perspective

The analysis of the monocyte activation tests market highlights key drivers such as increasing safety concerns among patients and a growing demand for safer pyrogen testing methods in industries like pharmaceuticals, biotechnology, and medical devices. Additionally, advancements in technology related to monocyte activation test methods are expected to drive market growth throughout the forecast period.

By source, the monocyte activation tests market is divided into PMBC and cell line categories. The PMBC segment held a larger market share in 2022 and is anticipated to maintain this trend during the forecast period. In terms of products, the market is categorized into MAT kits and reagents, with the MAT kits segment also holding a larger share in 2022 and expected to continue this trend. Conversely, the reagents segment is projected to experience a higher CAGR during the forecast period. The market is further segmented by application into drug development, vaccine development, medical devices, and others (such as research). The drug development segment accounted for the largest share in 2022 and is expected to maintain this trend from 2022 to 2030.

The monocyte activation test identifies enhanced cytokine release due to the combined effects of endotoxin and non-endotoxin pyrogens. The MAT is an in-vitro assay designed to evaluate parenteral drugs, biologics, and medical devices for all types of pyrogens. Over the past five years, vaccines that previously relied on the Rabbit Pyrogen Test for release assays have been among the first to adopt the monocyte activation test (MAT). Unlike MAT, bacterial endotoxin tests are often inadequate for products that are inherently pyrogenic or contain additives commonly found in vaccines, such as aluminum hydroxide, which can interfere with the assay. Examples of MAT's application in vaccine testing include the Neisseria meningitidis vaccine, Hyperimmune Sera, Meningococcal vaccines, Yellow fever vaccine, Shigella sonnei vaccine, Rabies vaccine, Hepatitis B Vaccine, and Tick-borne encephalitis virus vaccine.

Strategic Insights

Market Insights

Increasing Demand from the Medical Device Sector

Monocyte activation tests (MATs) are human cell-based assays used to detect and quantify pyrogens such as bacteria, fungi, and viruses. MATs employ an ELISA assay to measure cytokine release from treated blood cells. Although MATs are widely available, they are seldom used as substitutes for animal-based pyrogen tests in assessing the biocompatibility of medical devices. In September 2018, the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and the PETA International Science Consortium Ltd. (PISC) held a workshop at the National Institutes of Health to discuss the necessary steps for implementing MAT in medical device testing. According to Luxoft, a DXC Technology Company, medical devices are facilitating the digital transformation of healthcare by enabling accurate diagnoses, effective treatments, and personalized care through predictive algorithms and patient data analysis. Innovations in personalized medicine, implantable devices, smart medical devices, and non-invasive surgery are transforming the healthcare landscape by providing better care, improved patient outcomes, and reduced costs. The growth of the medical device industry has, in turn, supported the expansion of monocyte activation test methods and is expected to continue this trend during the forecast period.

Market Opportunity

Technological Advancements in Monocyte Activation Test Methods

Monocyte activation test methods were primarily introduced as alternatives to animal-based testing, providing the opportunity to conduct pyrogen testing in a human in vitro environment. The Monocyte Activation Test (MAT) was incorporated into the European Pharmacopeia (EP) in 2010 following international validation publications. Ongoing innovations and advancements in MAT assays and reagents by market players have significantly improved reproducibility, sensitivity, and specificity, making it a reliable and safer choice for pyrogen detection. The MAT assay is utilized to identify both endotoxins and non-endotoxin pyrogens in parenteral products, including pharmaceuticals and medical devices. Typically, the MAT serves as an in vitro alternative to traditional animal testing in compliance with regulatory guidelines. The Rabbit Pyrogen Test and the Limulus Amebocyte Lysate (LAL) test are commonly used for pyrogen detection, but both methods involve animal use and have certain limitations. The rabbit pyrogen test lacks robustness, as animal reactions may differ from human responses. Additionally, the LAL test only detects endotoxins, posing a safety risk by overlooking non-endotoxin pyrogens that may be present in the sample. To address these limitations, the monocyte activation test (MAT) was introduced in the European Pharmacopoeia in 2010 as a compendial method to replace the Rabbit Pyrogen Test (EP Chapter 2.6.30) and is specified in FDA guidance for industries. Continuous innovations and developments in MAT assays and reagents by market participants have led to enhancements in reproducibility, sensitivity, and specificity, establishing it as a reliable and safer option for pyrogen detection.

Report Segmentation and ScopeSource-based Insights

By source, the monocyte activation tests market is divided into PMBC and cell line categories. The PMBC segment held a larger market share in 2022 and is expected to maintain this trend during the forecast period, with a higher CAGR anticipated from 2022 to 2030. Currently, there are two commercialized sources of monocyte activation test cells available globally: the Mono-Mac-6 (MM6) cell line and Peripheral Blood Mononuclear Cells (PBMC). The MM6 cell line is derived from the blood of a single patient with acute monocytic leukemia, which can result in monocytes that do not consistently express TLRs necessary for detecting pyrogenic contaminants and triggering cytokine release as would occur in a healthy human. Consequently, the reproducibility of MAT results using this cell source has been found to be low. The Ph. Eur. (2.6.30) also describes MM6-based MAT kits as "limited" in their ability to detect non-endotoxin pyrogens. In contrast, PBMC-based MAT kits utilize PBMC sourced from pooled blood of screened, healthy donors, allowing for a more accurate simulation of human monocyte activation when incubated with a spiked product sample. As a result, MAT kits based on this cell source have consistently demonstrated reproducible results. The Ph. Eur. (2.6.30) recognizes this cell source as proficient in detecting both endotoxins and non-endotoxin pyrogens.

Currently, there are three other commercialized PBMC-based monocyte activation test vendors in the market, each with a limit of detection (LoD) of 0.125 EU/ml, 0.02 EU/ml, and 0.016 EU/ml. The CTL-MAT assay boasts one of the leading market LoDs at 0.004 EU/ml, making it the most sensitive monocyte activation test available globally.

Products-based InsightsIn terms of products, the monocyte activation tests market is divided into MAT kits and reagents. The MAT kits segment held a larger market share in 2022 and is expected to continue this trend during the forecast period, while the reagents segment is projected to experience a higher CAGR during the forecast period.

Application-based InsightsBy application, the monocyte activation tests market is segmented into drug development, vaccine development, medical devices, and others (such as research). The drug development segment captured the largest share in 2022 and is expected to maintain this trend from 2022 to 2030. According to the National Library of Medicine, pharmaceuticals are a group of emerging organic compounds that have significantly improved patients' quality of life. The pharmaceutical sector is involved in the production, development, and marketing of both branded and generic pharmaceuticals. For the first time in 2014, global pharmaceutical revenues surpassed US$ 1 trillion. The pharmaceutical market has been growing at an annual rate of 5.8% since 2017, with worldwide pharmaceutical market revenue reaching US$ 1,143 billion in 2017 and US$ 1,462 billion in 2021. The monocyte activation test (MAT) is designed to evaluate parenteral drugs, biologics, and medical devices for all classifications of pyrogens. Parenteral-administered pharmaceutical products must be free from pyrogenic (fever-inducing) contamination, as these substances can trigger a life-threatening systemic response in the patient's innate immune system. Ensuring that biological products are free from contaminating pyrogenic material before administration to patients is crucial. Initially, the Rabbit Pyrogen Test (RPT) and the Bacterial Endotoxin Test (BET)/Limulus Amebocyte Lysate Assay (LAL) were used as ex-vivo options.

However, stringent regulations regarding animal testing methods have compelled market participants to develop alternative methods that minimize animal use. Given the limitations of the RPT and BET, along with the increasing production of complex products, the European Pharmacopoeia introduced MAT activation testing methods that simulate the human immune response and combine the advantages of the RPT (assessing pyrogenicity beyond gram-negative endotoxin) with the benefits of an in vitro method. Unlike the RPT, MAT can be applied as a fully quantitative test without animal use, making it more suitable for inherently pyrogenic vaccines and physiologically relevant since it utilizes human cells. MAT testing assays can detect blood-derived products, cell-derived products, biologics, and vaccines. The MAT testing methods can also assess a wide range of drug products and medical devices, including those that cannot undergo in vivo testing (for example, products containing hyaluronic acid). These factors have contributed to the overall growth of the monocyte activation tests market in recent years and are expected to continue this trend during the forecast period.

Monocyte Activation Tests Market Report Scope

Regional Analysis

Regionally, the monocyte activation tests market is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. North America held the largest market share in 2022 and is expected to maintain this trend during the forecast period, followed by Europe. Regulatory practices governing monocyte activation tests by organizations such as the United States Pharmacopeia (USP) and the Government of Canada have further stimulated the overall growth of the monocyte activation tests market in the region. Additionally, an increasing focus on patient safety and improved healthcare outcomes is contributing to market growth in North America.

Leading companies in the monocyte activation tests market include Merck KGaA, Darmstadt, Germany and/or its affiliates; Charles River Laboratories International, Inc.; Thermo Fisher Scientific; Sanquin; and Lonza Group.

In October 2023, Lonza introduced two new rapid monocyte activation test (MAT) systems, the PyroCell MAT Rapid System and PyroCell MAT Human Serum (HS) Rapid System, aimed at simplifying and expediting rabbit-free pyrogen testing. These systems will replace Lonza's traditional MAT system kit offerings, and the newly launched products feature the new PeliKine Human IL-6 Rapid ELISA Kit, which reduces hands-on time and shortens time-to-results from two days to two hours. The new tests provide pharmaceutical and biotechnology manufacturers with more accessible MAT testing options for product safety testing while helping to decrease reliance on animal testing.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Monocyte Activation Tests Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Monocyte Activation Tests Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Monocyte Activation Tests Market - Global Market Analysis

  • 6.1 Monocyte Activation Tests - Global Market Overview
  • 6.2 Monocyte Activation Tests - Global Market and Forecast to 2030

7. Monocyte Activation Tests Market - Revenue Analysis (USD Million) - By Source, 2020-2030

  • 7.1 Overview
  • 7.2 PMBC
  • 7.3 Cell Line

8. Monocyte Activation Tests Market - Revenue Analysis (USD Million) - By Products, 2020-2030

  • 8.1 Overview
  • 8.2 MAT Kits
  • 8.3 Reagents

9. Monocyte Activation Tests Market - Revenue Analysis (USD Million) - By Application, 2020-2030

  • 9.1 Overview
  • 9.2 Drug Development
  • 9.3 Vaccine Development
  • 9.4 Medical Devices
  • 9.5 Others (Research etc.)

10. Monocyte Activation Tests Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Monocyte Activation Tests Market Overview
    • 10.1.2 North America Monocyte Activation Tests Market Revenue and Forecasts to 2030
    • 10.1.3 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Source
    • 10.1.4 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Products
    • 10.1.5 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Application
    • 10.1.6 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Monocyte Activation Tests Market
        • 10.1.6.1.1 United States Monocyte Activation Tests Market, by Source
        • 10.1.6.1.2 United States Monocyte Activation Tests Market, by Products
        • 10.1.6.1.3 United States Monocyte Activation Tests Market, by Application
      • 10.1.6.2 Canada Monocyte Activation Tests Market
        • 10.1.6.2.1 Canada Monocyte Activation Tests Market, by Source
        • 10.1.6.2.2 Canada Monocyte Activation Tests Market, by Products
        • 10.1.6.2.3 Canada Monocyte Activation Tests Market, by Application
      • 10.1.6.3 Mexico Monocyte Activation Tests Market
        • 10.1.6.3.1 Mexico Monocyte Activation Tests Market, by Source
        • 10.1.6.3.2 Mexico Monocyte Activation Tests Market, by Products
        • 10.1.6.3.3 Mexico Monocyte Activation Tests Market, by Application
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Pre and Post Covid-19 Impact

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Monocyte Activation Tests Market - Key Company Profiles

  • 14.1 Merck KGaA, Darmstadt,Germany and/or its Affiliates
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Charles River Laboratories International, Inc.
  • 14.3 Thermo Fisher Scientific
  • 14.4 Sanquin
  • 14.5 Lonza Group
  • 14.6 MAT Biotech
  • 14.7 Cellmade Laboratories
  • 14.8 Labor LS SE & Co. KG
  • 14.9 BD Biosciences
  • 14.10 Beckman Coulter

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud